Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases

Tampere University Hospital

Status: Active, not recruiting

Conditions: Residual Disease; Colorectal Cancer

Treatments: Diagnostic Test: blood draw

Study type: Interventional

Funder types: Other

Identifiers

NCT03189576

ETL R15085

Details and patient eligibility

About

Circulating tumour DNA (ctDNA) is a promising tool when monitoring the residual disease in colorectal cancer (CRC). Current staging procedures are insufficient to identify the patient cohort at high risk, who might benefit from additional adjuvant therapy.

We will show that the assessment of ctDNA is a non-invasive approach and easily taken at different time points via simple blood draw to monitor residual disease from the colorectal cancer patients after primary surgery. Minimal residual disease could be used in the future for individualized treatment decisions after primary surgery.

Enrollment: 37 estimated patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• planned colorectal primary surgery

Exclusion criteria

• unfit patients with dementia

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

37 participants in 1 patient group

CRC patients after primary surgery

Other group

Description:

sequential blood draw taken to monitor residual disease

Treatment:

Diagnostic Test: blood draw